P1275: Safety and Efficacy of Human Amniotic Epithelial Stem Cells Eye Drop in Ocular Chronic Graft-Versus-Host Disease

Abstract

Around 50% of patients suffer from ocular chronic GVHD (ocGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT), which causes serious dryness and visual impairment. Nevertheless, the current clinical therapies for ocGVHD including artificial tears, immunosuppression therapy, or punctual occlusion usually provide limited benefits. Amniotic membrane transplantation (AMT) can significantly alleviate ocular symptoms in ocGVHD patients, but AMT is an invasive surgery and is not applicable to all patients with ocGVHD. Therefore, we designed a clinical trial to demonstrate the safety and efficacy of human amniotic epithelial stem cells (hAESC) eye drops in ocGVHD.